You just read:

RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders

News provided by

RXi Pharmaceuticals Corporation

Jan 14, 2014, 07:02 EST